March 27 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns. On Thursday ...

Eye health company Bausch & Lomb is recalling some of its intraocular lenses over possible safety concerns. The voluntary recall comes after the company “received reports of complications ...

Bausch + Lomb has recalled its intraocular lenses after ... Intraocular lenses are surgically implanted into the eye, usually as part of cataract surgery, to replace the eye's natural lens.

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

See reviews below to learn more or submit your own review. Bausch & Lomb has manufactured eye health products and vision care solutions since 1853. The company is a global supplier of contact ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a prominent player in the global eye health market with a market capitalization of $5.78 billion, has been navigating a complex landscape of ...